Effectiveness of various therapy regimens for patients with pulmonary Langerhans cell histiocytosis during long-term follow-up

Zinchenko, Arina; Novikova, Lubov; Ilkovich, Mikhail M.

doi:10.1183/13993003.congress-2019.oa2142

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No association was identified between the presence of this mutation and disease presentation or outcome, in contrast to what has been reported in paediatric LCH populations who have higher risk of organ involvement. Two large retrospective studies, one from Russia and one from Poland, found a lack of response to corticosteroid therapy in LCH; conversely, cladribine was reported to be associated with 88-100% stabilisation/regression of the disease [69,70].…”

Section: Rare Ilds/dpldsmentioning

confidence: 98%

ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly

et al. 2020

View full text Add to dashboard Cite

This article discusses a selection of the scientific presentations in the field of interstitial lung diseases (ILDs) that took place at the 2019 European Respiratory Society International Congress in Madrid, Spain. There were sessions from all four groups within Assembly 12: group 12.01 “Idiopathic interstitial pneumonias”, group 12.02 “ILDs/diffuse parenchymal lung diseases (DPLDs) of known origin”, group 12.03 “Sarcoidosis and other granulomatous ILDs/DPLDs” and group 12.04 “Rare ILDs/DPLDs”. The presented studies brought cutting-edge developments on several aspects of these conditions, including pathogenesis, diagnosis and treatment. As many of the ILDs are individually rare, the sharing of experiences and new data that occur during the Congress are very important for physicians interested in ILDs and ILD patients alike.

show abstract

Section: Rare Ilds/dpldsmentioning

confidence: 98%